Patient derived organoids to model rare prostate cancer phenotypes

Loredana Puca; Rohan Bareja; Davide Prandi; Reid Shaw; Matteo Benelli; Wouter R. Karthaus; Judy Hess; Michael Sigouros; Adam Donoghue; Myriam Kossai; Dong Gao; Joanna Cyrta; Verena Sailer; Aram Vosoughi; Chantal Pauli; Yelena Churakova; Cynthia Cheung; Lesa Dayal Deonarine; Terra J. McNary; Rachele Rosati; Scott T. Tagawa; David M. Nanus; Juan Miguel Mosquera; Charles L. Sawyers; Yu Chen; Giorgio Inghirami; Rema A. Rao; Carla Grandori; Olivier Elemento; Andrea Sboner; Francesca Demichelis; Mark A. Rubin; Himisha Beltran

doi:10.1038/s41467-018-04495-z

Patient derived organoids to model rare prostate cancer phenotypes

Loredana Puca, Rohan Bareja, Davide Prandi, Reid Shaw, Matteo Benelli, Wouter R. Karthaus, Judy Hess, Michael Sigouros, Adam Donoghue, Myriam Kossai, Dong Gao, Joanna Cyrta, Verena Sailer, Aram Vosoughi, Chantal Pauli, Yelena Churakova, Cynthia Cheung, Lesa Dayal Deonarine, Terra J. McNary, Rachele RosatiScott T. Tagawa, David M. Nanus, Juan Miguel Mosquera, Charles L. Sawyers, Yu Chen, Giorgio Inghirami, Rema A. Rao, Carla Grandori, Olivier Elemento, Andrea Sboner, Francesca Demichelis, Mark A. Rubin, Himisha Beltran^*

^*Corresponding author for this work

Institute of Pathology

292 Citations (Scopus)

Abstract

A major hurdle in the study of rare tumors is a lack of existing preclinical models. Neuroendocrine prostate cancer is an uncommon and aggressive histologic variant of prostate cancer that may arise de novo or as a mechanism of treatment resistance in patients with pre-existing castration-resistant prostate cancer. There are few available models to study neuroendocrine prostate cancer. Here, we report the generation and characterization of tumor organoids derived from needle biopsies of metastatic lesions from four patients. We demonstrate genomic, transcriptomic, and epigenomic concordance between organoids and their corresponding patient tumors. We utilize these organoids to understand the biologic role of the epigenetic modifier EZH2 in driving molecular programs associated with neuroendocrine prostate cancer progression. High-throughput organoid drug screening nominated single agents and drug combinations suggesting repurposing opportunities. This proof of principle study represents a strategy for the study of rare cancer phenotypes.

Original language	English
Article number	2404
Journal	Nature Communications
Volume	9
Issue number	1
ISSN	1751-8628
DOIs	https://doi.org/10.1038/s41467-018-04495-z
Publication status	Published - 01.12.2018

Funding

We acknowledge assistance from the Molecular Cytology Core Facility at Memorial Sloan-Kettering Cancer Center (NIH Core Grant P30 CA 008748), the Translational Research Program at WCMC Pathology and Laboratory Medicine, and the WCM CLC Genomics and Epigenomics Core Facility. This study was supported by the Prostate Cancer Foundation (L.P., H.B.), American Italian Cancer Foundation (L.P.), European Research Council ERCCoG648670 (F.D.), Damon Runyon Cancer Research Foundation CI-67-13 (H.B.), Starr Cancer Consortium I7-A771 (Y.C., M.A.R, H.B.), Department of Defense PCRP PC121341 (H.B.), PC160264 (H.B), PC131961 (D.M.N., S.T.T., H.B.), and the National Cancer Institute 1U54CA210184-01 (H.B.) and WCM Prostate Cancer SPORE 1 P50 CA211024-01A1 (J.M.M., O.E., H.B.). The authors thank Drs. Ari Melnick and Wendy Beguelin at Weill Cornell Medicine for sharing short-harpin EZH2 plasmids. We acknowledge assistance from the Molecular Cytology Core Facility at Memorial Sloan-Kettering Cancer Center (NIH Core Grant P30 CA 008748), the Translational Research Program at WCMC Pathology and Laboratory Medicine, and the WCM CLC Genomics and Epigenomics Core Facility. This study was supported by the Prostate Cancer Foundation (L.P., H.B.), American Italian Cancer Foundation (L.P.), European Research Council ERCCoG648670 (F.D.), Damon Runyon Cancer Research Foundation CI-67-13 (H.B.), Starr Cancer Consortium I7-A771 (Y.C., M.A.R, H.B.), Department of Defense PCRP PC121341 (H.B.), PC160264 (H.B), PC131961 (D.M.N., S.T.T., H.B.), and the National Cancer Institute 1U54CA210184-01 (H.B.) and WCM Prostate Cancer SPORE 1 P50 CA211024-01A1 (J.M.M., O.E., H.B.).

Research Areas and Centers

Research Area: Luebeck Integrated Oncology Network (LION)
Centers: University Cancer Center Schleswig-Holstein (UCCSH)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41467-018-04495-z

Cite this

Puca, L., Bareja, R., Prandi, D., Shaw, R., Benelli, M., Karthaus, W. R., Hess, J., Sigouros, M., Donoghue, A., Kossai, M., Gao, D., Cyrta, J., Sailer, V., Vosoughi, A., Pauli, C., Churakova, Y., Cheung, C., Deonarine, L. D., McNary, T. J., ... Beltran, H. (2018). Patient derived organoids to model rare prostate cancer phenotypes. Nature Communications, 9(1), Article 2404. https://doi.org/10.1038/s41467-018-04495-z

@article{b1b575dbd8c54369a55c10619df6936e,

title = "Patient derived organoids to model rare prostate cancer phenotypes",

abstract = "A major hurdle in the study of rare tumors is a lack of existing preclinical models. Neuroendocrine prostate cancer is an uncommon and aggressive histologic variant of prostate cancer that may arise de novo or as a mechanism of treatment resistance in patients with pre-existing castration-resistant prostate cancer. There are few available models to study neuroendocrine prostate cancer. Here, we report the generation and characterization of tumor organoids derived from needle biopsies of metastatic lesions from four patients. We demonstrate genomic, transcriptomic, and epigenomic concordance between organoids and their corresponding patient tumors. We utilize these organoids to understand the biologic role of the epigenetic modifier EZH2 in driving molecular programs associated with neuroendocrine prostate cancer progression. High-throughput organoid drug screening nominated single agents and drug combinations suggesting repurposing opportunities. This proof of principle study represents a strategy for the study of rare cancer phenotypes.",

author = "Loredana Puca and Rohan Bareja and Davide Prandi and Reid Shaw and Matteo Benelli and Karthaus, \{Wouter R.\} and Judy Hess and Michael Sigouros and Adam Donoghue and Myriam Kossai and Dong Gao and Joanna Cyrta and Verena Sailer and Aram Vosoughi and Chantal Pauli and Yelena Churakova and Cynthia Cheung and Deonarine, \{Lesa Dayal\} and McNary, \{Terra J.\} and Rachele Rosati and Tagawa, \{Scott T.\} and Nanus, \{David M.\} and Mosquera, \{Juan Miguel\} and Sawyers, \{Charles L.\} and Yu Chen and Giorgio Inghirami and Rao, \{Rema A.\} and Carla Grandori and Olivier Elemento and Andrea Sboner and Francesca Demichelis and Rubin, \{Mark A.\} and Himisha Beltran",

note = "Publisher Copyright: {\textcopyright} 2018 The Author(s).",

year = "2018",

month = dec,

day = "1",

doi = "10.1038/s41467-018-04495-z",

language = "English",

volume = "9",

journal = "Nature Communications",

issn = "1751-8628",

publisher = "John Wiley \& Sons Inc.",

number = "1",

}

Puca, L, Bareja, R, Prandi, D, Shaw, R, Benelli, M, Karthaus, WR, Hess, J, Sigouros, M, Donoghue, A, Kossai, M, Gao, D, Cyrta, J, Sailer, V, Vosoughi, A, Pauli, C, Churakova, Y, Cheung, C, Deonarine, LD, McNary, TJ, Rosati, R, Tagawa, ST, Nanus, DM, Mosquera, JM, Sawyers, CL, Chen, Y, Inghirami, G, Rao, RA, Grandori, C, Elemento, O, Sboner, A, Demichelis, F, Rubin, MA & Beltran, H 2018, 'Patient derived organoids to model rare prostate cancer phenotypes', Nature Communications, vol. 9, no. 1, 2404. https://doi.org/10.1038/s41467-018-04495-z

TY - JOUR

T1 - Patient derived organoids to model rare prostate cancer phenotypes

AU - Puca, Loredana

AU - Bareja, Rohan

AU - Prandi, Davide

AU - Shaw, Reid

AU - Benelli, Matteo

AU - Karthaus, Wouter R.

AU - Hess, Judy

AU - Sigouros, Michael

AU - Donoghue, Adam

AU - Kossai, Myriam

AU - Gao, Dong

AU - Cyrta, Joanna

AU - Sailer, Verena

AU - Vosoughi, Aram

AU - Pauli, Chantal

AU - Churakova, Yelena

AU - Cheung, Cynthia

AU - Deonarine, Lesa Dayal

AU - McNary, Terra J.

AU - Rosati, Rachele

AU - Tagawa, Scott T.

AU - Nanus, David M.

AU - Mosquera, Juan Miguel

AU - Sawyers, Charles L.

AU - Chen, Yu

AU - Inghirami, Giorgio

AU - Rao, Rema A.

AU - Grandori, Carla

AU - Elemento, Olivier

AU - Sboner, Andrea

AU - Demichelis, Francesca

AU - Rubin, Mark A.

AU - Beltran, Himisha

PY - 2018/12/1

Y1 - 2018/12/1

N2 - A major hurdle in the study of rare tumors is a lack of existing preclinical models. Neuroendocrine prostate cancer is an uncommon and aggressive histologic variant of prostate cancer that may arise de novo or as a mechanism of treatment resistance in patients with pre-existing castration-resistant prostate cancer. There are few available models to study neuroendocrine prostate cancer. Here, we report the generation and characterization of tumor organoids derived from needle biopsies of metastatic lesions from four patients. We demonstrate genomic, transcriptomic, and epigenomic concordance between organoids and their corresponding patient tumors. We utilize these organoids to understand the biologic role of the epigenetic modifier EZH2 in driving molecular programs associated with neuroendocrine prostate cancer progression. High-throughput organoid drug screening nominated single agents and drug combinations suggesting repurposing opportunities. This proof of principle study represents a strategy for the study of rare cancer phenotypes.

AB - A major hurdle in the study of rare tumors is a lack of existing preclinical models. Neuroendocrine prostate cancer is an uncommon and aggressive histologic variant of prostate cancer that may arise de novo or as a mechanism of treatment resistance in patients with pre-existing castration-resistant prostate cancer. There are few available models to study neuroendocrine prostate cancer. Here, we report the generation and characterization of tumor organoids derived from needle biopsies of metastatic lesions from four patients. We demonstrate genomic, transcriptomic, and epigenomic concordance between organoids and their corresponding patient tumors. We utilize these organoids to understand the biologic role of the epigenetic modifier EZH2 in driving molecular programs associated with neuroendocrine prostate cancer progression. High-throughput organoid drug screening nominated single agents and drug combinations suggesting repurposing opportunities. This proof of principle study represents a strategy for the study of rare cancer phenotypes.

UR - https://www.scopus.com/pages/publications/85048751591

U2 - 10.1038/s41467-018-04495-z

DO - 10.1038/s41467-018-04495-z

M3 - Journal articles

C2 - 29921838

AN - SCOPUS:85048751591

SN - 1751-8628

VL - 9

JO - Nature Communications

JF - Nature Communications

IS - 1

M1 - 2404

ER -

Patient derived organoids to model rare prostate cancer phenotypes

Abstract

Funding

Research Areas and Centers

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this